March 2020 - Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks

In March's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the decision to extend the license for dapagliflozin 5 mg tablets to include use by people with type 1 diabetes and highlight concerns over the incidence of diabetic ketoacidosis. They review an article on managing asthma before and during pregnancy and talk about a case of partial nephrogenic diabetes insipidus associated with lithium therapy. Read the full March issue: dtb.bmj.com/content/58/3

If you enjoy the podcast, please subscribe to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment at https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. Thank you for listening.